

Hanan F Abdul-Rahim

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4176489/hanan-f-abdul-rahim-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

1,763

citations

22

h-index

41

g-index

70

ext. papers

3,708

ext. citations

15.1

avg, IF

4.81

L-index

#	Paper	IF	Citations
62	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.. <i>Nature Communications</i> , 2022 , 13, 532	17.4	13
61	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2.. <i>PLoS ONE</i> , 2022 , 17, e0262897	3.7	0
60	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	52
59	Iron Overload in Chronic Kidney Disease: Less Ferritin, More T2MRI.. <i>Frontiers in Medicine</i> , 2022 , 9, 865669	4.9	2
58	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	36
57	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022 , 13,	17.4	12
56	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1830-e1840	11.6	99
55	Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals. <i>Journal of Travel Medicine</i> , 2021 ,	12.9	4
54	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study.. <i>PLoS Medicine</i> , 2021 , 18, e1003879	11.6	19
53	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021 ,	50.5	104
52	Severity, criticality, and fatality of the SARS-CoV-2 Beta variant. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	8
51	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021 , 385, e83	59.2	226
50	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1930-1939	27.4	45
49	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2021 , 11, 6233	4.9	57
48	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. <i>BMJ Innovations</i> , 2021 , 7, 327-336	1.8	15
47	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab221	1	23
46	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. <i>Emerging Infectious Diseases</i> , 2021 , 27, 1343-1352	10.2	38

45	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021 , 28,	12.9	33
44	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021 , 35, 100861	11.3	77
43	Students' perceptions of a university's No Smoking Policy and barriers to implementation: a cross-sectional study. <i>BMJ Open</i> , 2021 , 11, e043691	3	2
42	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. <i>iScience</i> , 2021 , 24, 102646	6.1	39
41	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. <i>Scientific Reports</i> , 2021 , 11, 11837	4.9	7
40	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021 , 27, 1614-1621	50.5	144
39	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. <i>Infection, Genetics and Evolution</i> , 2021 , 88, 104684	4.5	10
38	Prevalence, Risk Factors, Harm Perception, and Attitudes Toward E-cigarette Use Among University Students in Qatar: A Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2021 , 9, 682355	6	1
37	Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February-18 April 2020. <i>BMJ Open</i> , 2020 , 10, e040428	3	55
36	Willingness to participate in genome testing: a survey of public attitudes from Qatar. <i>Journal of Human Genetics</i> , 2020 , 65, 1067-1073	4.3	2
35	The Reproductive Agency Scale (RAS-17): development and validation in a cross-sectional study of pregnant Qatari and non-Qatari Arab Women. <i>BMC Pregnancy and Childbirth</i> , 2020 , 20, 503	3.2	4
34	Validation of three mental health scales among pregnant women in Qatar. <i>Reproductive Health</i> , 2019 , 16, 149	3.5	2
33	Human and economic resources for empowerment and pregnancy-related mental health in the Arab Middle East: a systematic review. <i>Archives of Women's Mental Health</i> , 2019 , 22, 1-14	5	5
32	Social resources and Arab women's perinatal mental health: A systematic review. <i>Women and Birth</i> , 2018 , 31, 386-397	3.3	4
31	The effects of citizenship status on service utilization and general satisfaction with healthcare: a cross-cultural study. <i>International Journal for Quality in Health Care</i> , 2017 , 29, 47-54	1.9	2
30	Non-communicable diseases in the Arab world. <i>Lancet, The</i> , 2014 , 383, 356-67	40	235
29	Dietary habits of Palestinian adolescents and associated sociodemographic characteristics in Ramallah, Nablus and Hebron governorates. <i>Public Health Nutrition</i> , 2010 , 13, 1419-29	3.3	11
28	Prevalence and sociodemographic correlates of stunting, underweight, and overweight among Palestinian school adolescents (13-15 years) in two major governorates in the West Bank. <i>BMC Public Health</i> , 2009 , 9, 485	4.1	31

27	Cesarean section deliveries in the occupied Palestinian territory (oPt): an analysis of the 2006 Palestinian Family Health Survey. <i>Health Policy</i> , 2009 , 93, 151-6	3.2	11
26	Maternal and child health in the occupied Palestinian territory. <i>Lancet, The</i> , 2009 , 373, 967-77	4.0	65
25	Health sector reform in the Occupied Palestinian Territories (OPT): targeting the forest or the trees?. <i>Health Policy and Planning</i> , 2003 , 18, 59-67	3.4	41
24	Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant		8
23	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar		3
22	Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar		6
21	Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar		2
20	Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar		2
19	Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design		4
18	Gender and trust in government modify the association between mental health and stringency of social distancing related public health measures to reduce COVID-19: a global online survey		5
17	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic		21
16	Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting		36
15	COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar		3
14	Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections		5
13	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2		1
12	Inclusion of cycle threshold (CT) values when reporting SARS-CoV-2 RT-PCR results improves clinical Interpretation in suspected and confirmed COVID-19		1
11	Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection		9
10	Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar		22

9	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar	32
8	Severity, criticality, and fatality of the SARS-CoV-2 Beta variant	2
7	SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients	2
6	SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks	20
5	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage	6
4	Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections	3
3	Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar	2
2	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar	5
1	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> ,	59.2 24